tbResList Print — H2 Hydrogen Gas

Description: <b>Hydrogen Gas</b>, Powerful Antioxidant <br>
Mechanistically, H₂ is most defensibly framed as a selective antioxidant + anti-inflammatory signaling modulator (often via Nrf2↑ and NF-κB↓ / NLRP3↓), with strongest clinical relevance in oncology being reduction of treatment toxicities (radiation/CCRT side-effects), with mixed/early evidence for direct anticancer effects. <br>
<br>
1.Antioxidant and Nrf2/ARE Pathway: activate Nrf2, which induces antioxidant enzymes. <br>
2.NF-κB Pathway: reported to inhibit NF-κB activation, thereby reducing inflammatory cytokine production <br>
3.Mitochondrial Apoptosis Pathway <br>
4.MAPK (Mitogen-Activated Protein Kinases) Pathway <br>
5.PI3K/Akt/mTOR Pathway <br>
6.Inflammatory Cytokine Signaling: Reducing cytokines (such as IL-6, TNF-α) <br>
7.p53 Pathway <br>
8.Autophagy Pathways: might regulate autophagy, (dual roles in cancer) <br>
<br>
<a href="https://suiso-madoguchi.com/product/11/">Example unit sometimes used in studies</a><br>
<a href="https://qlifecanada.ca/">Example Canadian Supplier</a><br>
<br>
Hydrogen gas can be generated in small amount by hydrogenase of certain members of the human gastrointestinal tract microbiota from unabsorbed carbohydrates in the intestine through degradation and metabolism, which then is partially diffused into blood flow and released and detected in exhaled breath, indicating its potential to serve as a biomarker.<br>
<br>
<a href="tbResList.php?qv=295&wNotes=on">Many studies</a>
have shown that H2 therapy can reduce oxidative stress. This, however, contradicts radiation therapy and chemotherapy, in which ROS are required to induce apoptosis and combat cancer. Yet many studies show
<a href="tbResList.php?qv=295&tsv=1171&wNotes=on">chemoprotective</a>
and
<a href="tbResList.php?qv=295&tsv=1185&wNotes=on">radioprotective</a>
and some even show
<a href="tbResList.php?qv=295&tsv=1106&wNotes=on">chemosentizing</a>
<br>
Nevertheless there are some papers claiming
<a href="tbResList.php?qv=295&&tsv=275&esv=2&exSp=open&wNotes=on"> ROS ↑</a>
for cancer cells<br>
<br>
Hydrogen Gas in Water is also used. <br>
- the amount of H2 dissolved in solutions is limited: up to 0.8 mM (1.6 mg/L) H2 can be dissolved in water under atmospheric pressure at room temperature<br>
<br>

<br>
<p><b>Hydrogen Gas</b> — molecular hydrogen (H₂) is a small, neutral diatomic gas investigated as a therapeutic medical gas and redox-signaling modulator. It rapidly diffuses across biological membranes and can be administered by inhalation or indirectly as hydrogen-rich water (HRW), hydrogen-rich saline, or hydrogen-releasing materials. H₂ is best classified as an experimental therapeutic gas rather than a conventional antioxidant drug. Standard abbreviations are H₂ for molecular hydrogen and HRW for hydrogen-rich water. Endogenous H₂ is also produced by intestinal microbial fermentation. Its biological effects appear to involve modulation of oxidative stress, inflammation, mitochondrial function, cell-death signaling, and immune metabolism rather than indiscriminate ROS scavenging alone.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Redox modulation and selective suppression of highly damaging oxidative/nitrosative stress, with secondary NRF2-dependent antioxidant adaptation.</li>
<li>Suppression of inflammatory signaling, particularly NF-κB and associated cytokine pathways.</li>
<li>Mitochondrial and metabolic modulation, including preservation or remodeling of mitochondrial bioenergetics and PGC-1α-linked signaling.</li>
<li>Immune modulation, including reported restoration of metabolically exhausted CD8+ T-cell function in cancer.</li>
<li>Context-dependent regulation of tumor-cell ROS, apoptosis, pyroptosis, differentiation, proliferation, and PI3K/Akt/mTOR signaling.</li>
<li>Protection of normal tissues from chemotherapy- and radiotherapy-associated oxidative and inflammatory injury.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> H₂ has unusually rapid tissue diffusion because of its very small, nonpolar structure, but tissue exposure is transient because hydrogen is rapidly redistributed and exhaled. Inhalation provides continuing systemic exposure during administration, whereas HRW delivers a comparatively small finite H₂ dose that falls rapidly after preparation and ingestion. At approximately atmospheric pressure and room temperature, water saturation is only about 1.6 mg/L H₂, approximately 0.8 mmol/L. Biological efficacy therefore depends strongly on route, concentration, treatment duration, and proximity of H₂ generation to the target tissue.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> H₂ does not behave like a conventional concentration-maintained small-molecule drug. Gas-equilibrated cell culture can provide sustained H₂ exposure that is difficult to reproduce with a single oral dose of HRW. Conversely, inhalation can continuously replenish dissolved H₂ during treatment. Results from prolonged gas-equilibrated cultures, high-pressure systems, or locally generated H₂ nanomaterials should therefore not automatically be extrapolated to ordinary hydrogen-water exposure.</p>

<p><b>Clinical evidence status:</b> Small human studies and randomized adjunctive trials exist, but H₂ is not an established anticancer therapy. The most credible oncology application currently is supportive treatment during chemotherapy or radiotherapy. A 2025 randomized study in cervical-cancer patients receiving concurrent chemoradiotherapy reported reduced acute radiation enteritis and inflammatory responses with adjunctive H₂/O₂ inhalation without an apparent reduction in tumor-control efficacy. Direct antitumor evidence remains predominantly preclinical, observational, or derived from small uncontrolled cancer cohorts. Trials of HRW during glioma radiochemotherapy and other indications remain exploratory. H₂ should therefore be classified as experimental adjunct/supportive therapy rather than standalone cancer treatment.</p>





<h3>Hydrogen Gas Cancer-Relevant Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>Redox and reactive oxygen species regulation</td>
<td>ROS ↑ or ↓ (model-dependent)</td>
<td>Excess ROS ↓; oxidative damage ↓</td>
<td>P, R</td>
<td>Redox modulation</td>
<td>H₂ should not be treated as a simple universal ROS scavenger. Normal-tissue studies predominantly show reduced oxidative injury, whereas some tumor models paradoxically show ROS ↑ and ROS-dependent tumor cell death.</td>
</tr>

<tr>
<td>2</td>
<td>NRF2 antioxidant stress response</td>
<td>NRF2 ↔ or ↑ (context-dependent)</td>
<td>NRF2 ↑; HO-1 ↑; SOD ↑; GSH-associated defenses ↑</td>
<td>R, G</td>
<td>Adaptive antioxidant signaling</td>
<td>NRF2 activation is mechanistically important mainly for cytoprotection and stress adaptation rather than as a consistent direct anticancer mechanism.</td>
</tr>

<tr>
<td>3</td>
<td>NF-κB inflammatory signaling</td>
<td>NF-κB ↓ (context-dependent)</td>
<td>NF-κB ↓; inflammatory injury ↓</td>
<td>R, G</td>
<td>Anti-inflammatory signaling</td>
<td>Frequently accompanied by IL-6 ↓, TNF-α ↓ and IL-1β ↓. This pathway is particularly relevant to normal-tissue protection during inflammatory injury and cancer therapy.</td>
</tr>

<tr>
<td>4</td>
<td>Mitochondrial bioenergetics and PGC-1α</td>
<td>Mitochondrial function ↑ in exhausted immune cells; tumor response model-dependent</td>
<td>Mitochondrial damage ↓; ATP homeostasis ↑</td>
<td>R, G</td>
<td>Bioenergetic remodeling</td>
<td>H₂ can improve mitochondrial resilience. In cancer, an important proposed mechanism is metabolic restoration of exhausted antitumor lymphocytes rather than direct mitochondrial poisoning of tumor cells.</td>
</tr>

<tr>
<td>5</td>
<td>CD8 T-cell exhaustion and antitumor immunity</td>
<td>Indirect tumor suppression ↑</td>
<td>CD8+ T-cell metabolic fitness ↑</td>
<td>G</td>
<td>Immune restoration</td>
<td>Clinical observations in colorectal and lung cancer suggest restoration of exhausted CD8+ T-cell function, including mitochondrial and CoQ10-associated effects. Evidence remains preliminary.</td>
</tr>

<tr>
<td>6</td>
<td>PI3K Akt mTOR proliferative signaling</td>
<td>PI3K ↓; p-Akt ↓; mTOR signaling ↓ (model-dependent)</td>
<td>↔ or context-dependent</td>
<td>G</td>
<td>Growth suppression</td>
<td>Reported particularly in experimental colorectal-cancer models. This is not yet established as a reproducible systemic mechanism in patients.</td>
</tr>

<tr>
<td>7</td>
<td>NLRP3 caspase-1 GSDMD pyroptosis</td>
<td>ROS ↑; NLRP3 ↑; caspase-1 ↑; GSDMD-mediated pyroptosis ↑ (model-dependent)</td>
<td>NLRP3 commonly ↓ during inflammatory injury</td>
<td>R, G</td>
<td>Context-dependent inflammatory cell death</td>
<td>An important example of opposite modulation by biological context. H₂ induced ROS-dependent NLRP3-mediated pyroptosis in an endometrial-cancer model, whereas normal-tissue inflammatory models commonly show NLRP3 suppression.</td>
</tr>

<tr>
<td>8</td>
<td>Tumor proliferation and differentiation</td>
<td>Proliferation ↓; differentiation ↑ (model-dependent)</td>
<td>Generally ↔</td>
<td>G</td>
<td>Tumor phenotype modulation</td>
<td>Glioblastoma models report differentiation of glioma stem-like cells and reduced tumor growth. Generalization to other cancers is uncertain.</td>
</tr>

<tr>
<td>9</td>
<td>Angiogenesis and hypoxic signaling</td>
<td>HIF-1α ↓; VEGF ↓ (model-dependent)</td>
<td>VEGF responses mixed</td>
<td>G</td>
<td>Angiogenic suppression</td>
<td>Preclinical evidence suggests inhibition in selected tumor models but does not establish a general antiangiogenic clinical effect.</td>
</tr>

<tr>
<td>10</td>
<td>Glycolytic metabolism</td>
<td>HK2 ↓; PFK ↓; glycolysis ↓; lactate production ↓ (model-dependent)</td>
<td>↔ or context-dependent</td>
<td>G</td>
<td>Metabolic growth restriction</td>
<td>Reported in selected experimental cancer systems and should remain secondary until replicated across models.</td>
</tr>

<tr>
<td>11</td>
<td>Chemosensitization</td>
<td>Therapeutic response ↑ in selected models</td>
<td>Chemotherapy-associated organ injury ↓</td>
<td>G</td>
<td>Adjunctive treatment modulation</td>
<td>H₂ has produced both chemoprotective normal-tissue effects and occasional tumor chemosensitization. Protection of normal tissues should not be interpreted as established protection of tumors.</td>
</tr>

<tr>
<td>12</td>
<td>Radiotherapy tissue protection</td>
<td>Tumor control apparently ↔ in limited human data</td>
<td>Radiation-associated oxidative and inflammatory injury ↓</td>
<td>R, G</td>
<td>Supportive radioprotection</td>
<td>A randomized cervical-cancer study reported reduced acute radiation enteritis during chemoradiotherapy without evidence of compromised short-term antitumor efficacy. Larger confirmation is required.</td>
</tr>

<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>Direct anticancer efficacy unproven</td>
<td>Generally well tolerated in studied protocols</td>
<td>G</td>
<td>Exposure and evidence limitation</td>
<td>H₂ exposure varies substantially with inhaled concentration, flow, duration, HRW concentration, storage, and delivery technology. Gas mixtures containing high H₂ concentrations require engineered control because hydrogen is flammable and explosive in air. No standardized oncology dose or approved anticancer indication exists.</td>
</tr>
</table>
<p>P: 0–30 min &nbsp;&nbsp;&nbsp; R: 30 min–3 hr &nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>






<br><br>
<p><b>Hydrogen Gas and Alzheimer’s disease:</b> Molecular hydrogen has substantial preclinical neuroprotective evidence and limited early human evidence in Alzheimer’s disease and mild cognitive impairment. Proposed mechanisms include oxidative-stress suppression, neuroinflammation reduction, mitochondrial protection, BDNF-related signaling, and reductions in Aβ/BACE-associated pathology and tau phosphorylation. H₂ readily diffuses into the CNS, making delivery biologically plausible, but clinical evidence remains insufficient to classify it as a disease-modifying AD treatment.</p>

<p><b>Clinical evidence status:</b> Preclinical evidence is extensive relative to the small clinical literature. Human studies include an open-label inhalation pilot in AD, a single-arm biomarker study, and a randomized hydrogen-rich-water study in mild cognitive impairment. Reported cognitive or biomarker improvements are hypothesis-generating; adequately powered randomized trials with validated AD endpoints are still needed.</p>


<h3>Hydrogen Gas Alzheimer-Relevant Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>Oxidative and mitochondrial stress</td>
<td>ROS ↓; lipid oxidation ↓; mitochondrial damage ↓</td>
<td>P, R</td>
<td>Neuroprotection</td>
<td>One of the most consistently reproduced effects in experimental neurodegeneration models.</td>
</tr>

<tr>
<td>2</td>
<td>Neuroinflammatory signaling</td>
<td>NF-κB ↓; IL-1β ↓; IL-6 ↓; TNF-α ↓</td>
<td>R, G</td>
<td>Neuroinflammation suppression</td>
<td>Likely interconnected with redox and glial responses.</td>
</tr>

<tr>
<td>3</td>
<td>NRF2 antioxidant response</td>
<td>NRF2 ↑; HO-1 ↑; endogenous antioxidant defenses ↑</td>
<td>R, G</td>
<td>Cellular stress resistance</td>
<td>Secondary adaptive mechanism rather than simple chemical radical scavenging.</td>
</tr>

<tr>
<td>4</td>
<td>Amyloid beta and BACE signaling</td>
<td>Aβ ↓; BACE-associated processing ↓ (model-dependent)</td>
<td>G</td>
<td>Amyloid pathology reduction</td>
<td>Demonstrated mainly in experimental models; human disease-modifying evidence is not established.</td>
</tr>

<tr>
<td>5</td>
<td>Tau phosphorylation</td>
<td>p-tau ↓ (model-dependent)</td>
<td>G</td>
<td>Tau pathology attenuation</td>
<td>Supported primarily by animal and experimental hydrogen-delivery studies.</td>
</tr>

<tr>
<td>6</td>
<td>BDNF and neuronal plasticity</td>
<td>BDNF ↑; neuronal plasticity ↑</td>
<td>G</td>
<td>Cognitive and synaptic support</td>
<td>Reported across several neurologic injury models and investigated as a biomarker in human inhalation studies.</td>
</tr>

<tr>
<td>7</td>
<td>NLRP3 inflammasome</td>
<td>NLRP3 ↓</td>
<td>R, G</td>
<td>Microglial inflammatory suppression</td>
<td>Potential connection between oxidative stress, innate immune activation, and neurodegeneration.</td>
</tr>

<tr>
<td>8</td>
<td>Cognition and memory</td>
<td>Memory ↑; cognitive performance ↑ (model-dependent)</td>
<td>G</td>
<td>Functional outcome</td>
<td>Robust in several animal paradigms but human trials remain small and heterogeneous.</td>
</tr>

<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td>Evidence insufficient for established AD treatment</td>
<td>G</td>
<td>Clinical evidence limitation</td>
<td>Existing human studies are small, often uncontrolled, or use surrogate endpoints. Optimal concentration, inhalation duration, treatment schedule, and long-term efficacy remain unresolved.</td>
</tr>
</table>
<p>P: 0–30 min &nbsp;&nbsp;&nbsp; R: 30 min–3 hr &nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>